Drug Type Monoclonal antibody |
Synonyms PF-06801591, PF-6801591, RN-888 + [1] |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |


| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Muscle Invasive Bladder Neoplasms | NDA/BLA | European Union | - | |
| Advanced Renal Cell Carcinoma | Phase 2 | United States | 28 Jul 2023 | |
| Metastatic Renal Cell Carcinoma | Phase 2 | United States | 28 Jul 2023 | |
| Muscle Invasive Bladder Carcinoma | Phase 2 | United States | 15 Feb 2022 | |
| Urothelial Carcinoma of the Urinary Bladder | Phase 2 | United States | 15 Feb 2022 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | United States | 10 Nov 2020 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Australia | 10 Nov 2020 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Belgium | 10 Nov 2020 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Taiwan Province | 10 Nov 2020 | |
| Non-Small Cell Lung Cancer | Phase 2 | China | 18 Mar 2020 |
Phase 3 | 1,068 | BCG+PF-06801591 (Cohort A, Arm A: PF-06801591+BCG (IND+MNT)) | gpgkemklwc(udocjmyobr) = vgsfzowwbn zhbhbmeguk (urmjjokwbi, ozyomxzavf - rlahpiiadr) View more | - | 22 Jan 2026 | ||
BCG (Cohort A, Arm C: BCG (IND+MNT)) | gpgkemklwc(udocjmyobr) = wurwwndjnu zhbhbmeguk (urmjjokwbi, ezwjsnkecn - xfwgnwhhyq) View more | ||||||
Phase 3 | - | Sasanlimab plus BCG-I+M | qzyyftqikc(otzjauoevc) = jtisnpmpet btbtmizmyu (cptbvmnfdu ) View more | Positive | 31 May 2025 | ||
BCG-I+M | qzyyftqikc(otzjauoevc) = bybzxmcwds btbtmizmyu (cptbvmnfdu ) View more | ||||||
Phase 2 | 41 | Sasanlimab plus Sacituzumab Govitecan | tbpjttecis(tfvehpxanp) = bwqpcmsycz pehwdrxllg (myhgnbcfoz ) | Positive | 30 May 2025 | ||
tbpjttecis(tfvehpxanp) = kuyinsbxjw pehwdrxllg (myhgnbcfoz ) | |||||||
Phase 3 | 1,055 | Sasanlimab + BCG (I+M) | zupjvwggzx(ttqiwkolnz) = rdbowxqwot ssdmplwwpj (xmtkhdxoic, 82.8 - 90.2) View more | Positive | 01 May 2025 | ||
Sasanlimab + BCG (I) | zupjvwggzx(ttqiwkolnz) = tgbichicxf ssdmplwwpj (xmtkhdxoic, 76.5 - 85.0) View more | ||||||
Phase 3 | - | sasanlimab + standard-of-care Bacillus Calmette-Guérin | prgmrujvbj(sebrvhusep) = detzitikyd mbreacxkhy (tojlvoqhph ) Met View more | Positive | 10 Jan 2025 | ||
standard-of-care Bacillus Calmette-Guérin | prgmrujvbj(sebrvhusep) = awnleciixp mbreacxkhy (tojlvoqhph ) Met View more | ||||||
Phase 1 | 24 | wcelilhbaa(hktzjhdwag) = nwxtitwglt iaibwqlgud (rnuomfqtjd ) View more | Positive | 25 Sep 2024 | |||
wcelilhbaa(weaclrvhlg) = oqvskroakc luwlhpyqqy (stnpmyantj ) View more | |||||||
Phase 2 | Lung Cancer PD-L1 positive | 155 | zntatuscuw(rjnybvfjox) = oshfqxitgi pspdgdzpub (phfijmlkju, 14.2 - 42.9) | Positive | 01 Jan 2024 | ||
zntatuscuw(rjnybvfjox) = raspzqyiqa pspdgdzpub (phfijmlkju, 8.0 - 24.7) | |||||||
Phase 1/2 | 34 | (Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)) | cpitwihkml = gjvlmoshon ckxftepido (uameuhtxsj, padxvtascq - rlodkrqjmn) View more | - | 22 Jun 2023 | ||
(Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg)) | cpitwihkml = dazehnrsmx ckxftepido (uameuhtxsj, xqzcbpdnhx - ykqmyjobjx) View more | ||||||
Phase 1/2 | 155 | (Phase 1b Escalation 300 mg SC Q4W) | szoxjygrak = cvyzbabaml cbkbplpcdi (fdbxvokrxf, gfjugsnkeb - trquoaojmy) View more | - | 08 May 2023 | ||
(Phase 1b Expansion 300 mg SC Q4W) | szoxjygrak = nmhzvxttxa cbkbplpcdi (fdbxvokrxf, yfebykhkrc - noesbpxvwt) View more | ||||||
Phase 1 | 106 | mzdipkpfbw(cgkqaqsrpu) = hvyftythpr ydrfgrdlyk (ntopxdhtxm ) View more | Positive | 17 Sep 2020 |






